Lower Costs, More Cures Act of 2019

House Bill 19 - Lower Costs, More Cures Act of 2019: Overview, Status, and Impact

Hozzl · 2022-10-28T01:46:01Z

Explore the details of House Bill 19 Lower Costs, More Cures Act of 2019 currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

10/28/2022, 1:46 AM

Congressional Summary of HR 19

Lower Costs, More Cures Act of 2019

This bill establishes and modifies several requirements to address prescription drug prices under Medicare, Medicaid, and other programs.

The bill generally

limits payment amounts for drugs and biologics under Medicare medical services,
reduces cost-sharing under the Medicare prescription drug benefit,
modifies certain authorities and requirements under the Medicaid Drug Rebate Program,
revises provisions relating to regulatory approval and commercial availability of generics and biosimilars, and
establishes several reporting requirements for drug manufacturers with respect to drug prices.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill HR 19

Bill HR 19 is currently in the status of Bill Introduced since December 9, 2019. Bill HR 19 was introduced during Congress 116 and was introduced to the House on December 9, 2019. Bill HR 19's most recent activity was Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law. as of December 19, 2019

Bipartisan Support of Bill HR 19

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

147

Democrat Cosponsors

Republican Cosponsors

147

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill HR 19

Primary Policy Focus

Health

Potential Impact Areas

- Administrative law and regulatory procedures

- Administrative remedies

- Advisory bodies

- Appropriations

- Biological and life sciences

- Business records

- Cancer

- Chemistry

- Child health

- Civil actions and liability

- Competition and antitrust

- Congressional oversight

- Consumer affairs

- Corporate finance and management

- Cosmetics and personal care

- Department of Health and Human Services

- Digestive and metabolic diseases

- Drug safety, medical device, and laboratory regulation

- Drug therapy

- Executive agency funding and structure

- Federal Trade Commission (FTC)

- Food and Drug Administration (FDA)

- Fraud offenses and financial crimes

- Genetics

- Government information and archives

- Government studies and investigations

- Health care costs and insurance

- Health information and medical records

- Health personnel

- Health programs administration and funding

- Health technology, devices, supplies

- Home and outpatient care

- Hospital care

- Immunology and vaccination

- Income tax deductions

- Income tax exclusion

- Inflation and prices

- Intellectual property

- Intergovernmental relations

- Judicial review and appeals

- Licensing and registrations

- Manufacturing

- Marketing and advertising

- Medicaid

- Medical education

- Medical research

- Medical tests and diagnostic methods

- Medicare

- Office of the U.S. Trade Representative

- Prescription drugs

- Product development and innovation

- Public participation and lobbying

- Research and development

- Retail and wholesale trades

- State and local government operations

- Trade agreements and negotiations

- User charges and fees

- Women's health

Alternate Title(s) of Bill HR 19

Lower Costs, More Cures Act of 2019

To provide for certain reforms with respect to the Medicare program under title XVIII of the Social Security Act, the Medicaid program under title XIX of such Act, the Food and Drug Administration, and for other purposes.

Lower Costs, More Cures Act of 2019

Over-the-Counter Monograph User Fee Act of 2019

Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019